• Macrophages Link Intermittent Hypoxia to Pain

  2026-10-06

  Chivers and colleagues identify peripheral macrophages as a key contributor to nociceptor priming in mice exposed to chronic intermittent hypoxia, a model of recurrent oxygen loss associated with obstructive sleep apnea. By combining behavioral, neurobiological, and immune readouts with macrophage depletion, the study moves beyond correlation toward evidence that macrophage signaling is required for the observed persistent pain phenotype. The findings support further investigation of hypoxia correction and immune mechanisms, while remaining preclinical and model-dependent.

• Sunitinib: RTK Biology and Evidence Boundaries

  2026-10-05

  Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor that suppresses signaling through VEGFR, PDGFR, KIT, and RET. Research in ATRX-deficient high-grade glioma cells supports a biomarker-focused hypothesis for RTK inhibition, but the findings do not establish clinical efficacy in glioma.

• Drug-Sensitized Yeast for mTOR Inhibitor Discovery

  2026-10-05

  A 2025 GeroScience study developed a genetically drug-sensitized yeast platform that detected TOR pathway inhibition far more sensitively than a wild-type background. The system identified known and candidate TOR inhibitors while finding no evidence that canagliflozin inhibited TOR in this model, clarifying the boundary between SGLT2-focused glucose metabolism research and mTOR drug discovery.

• ABT-737 and BAX/BAK Apoptosis: Five Questions

  2026-10-04

  This source-grounded overview explains how ABT-737 is positioned as a BCL-2 protein inhibitor, how the 2024 BAX/BAK imaging study informs apoptosis biology, and where the evidence does—and does not—support conclusions about cancer research.

• Hexa-Acylated LPS and Cancer Immunotherapy Response

  2026-10-03

  A 2025 Nature Microbiology study links the structural form of gut microbiota-derived lipopolysaccharide, rather than bacterial taxonomy alone, to response to anti-PD-1 immunotherapy. Functional metagenomics and mouse-model experiments support hexa-acylated LPS as a mechanistic contributor and a possible response-associated biomarker, while also defining important limits on clinical interpretation.

• Tetramethylrhodamine ethyl ester perchlorate: TMRE Guide

  2026-10-02

  Tetramethylrhodamine ethyl ester perchlorate enables live, quantitative tracking of mitochondrial membrane potential in microscopy and flow cytometry workflows. This guide connects TMRE staining to toxin-induced liver injury research, showing how to distinguish mitochondrial depolarization from broader ROS and apoptosis signals.

• Geneticin, G-418 Sulfate: Selection Workflow

  2026-10-01

  Geneticin, G-418 Sulfate (SKU A2513) provides selection pressure for cells carrying a neomycin resistance gene and can support context-specific Dengue virus serotype 2 assays. It should be optimized with a cell-line kill curve and appropriate controls, and it should not be treated as a universal antiviral concentration or a substitute for a validated biosafety and cytotoxicity workflow.

• Clodronate Liposomes for In Vivo Macrophage Studies

  2026-10-01

  Learn how to use Clodronate Liposomes to test macrophage-dependent mechanisms in tumors, inflammation, and transgenic mouse models without confusing depletion with immune-cell reprogramming. This workflow connects route selection, PBS-liposome controls, flow-cytometry verification, and the CCL7–TAM findings reported in colorectal cancer immunotherapy resistance.

• Chronic Cabozantinib Rewires RCC Phosphoproteomes

  2026-09-30

  A 2026 phosphoproteomic study distinguishes the signaling consequences of acute versus chronic Cabozantinib exposure in renal cell carcinoma cells. Its central contribution is the identification of selective adhesion-, stress-, and MAPK/AP-1-associated remodeling during long-term treatment, despite persistent suppression of MET activation-loop phosphorylation.

• Nutlin-3a MDM2 Inhibitor Workflow

  2026-09-30

  Build a reproducible Nutlin-3a workflow for p53 pathway activation, cell-cycle profiling, and apoptosis induction while testing the miR-18a–ALOXE3 ferroptosis axis described in glioblastoma research. The framework separates established MDM2 pharmacology from exploratory cross-pathway hypotheses, helping researchers choose informative controls and troubleshoot variable responses.

• Q7j and HER2–EMT Inhibition in Breast Cancer

  2026-09-29

  A 2022 European Journal of Medicinal Chemistry study used a Mubritinib-derived scaffold to create 32 novel HER2 inhibitor candidates and identified Q7j as the leading compound. Q7j reduced HER2 phosphorylation, altered EMT-associated protein expression, limited breast cancer cell migration, and outperformed the parent compound in an SKBR3 orthotopic xenograft model.

• ML216: A Precision Tool for Helicase Dependency

  2026-09-29

  ML216 is a BLM helicase inhibitor for dissecting DNA repair vulnerability, homologous recombination, and tumor cell sensitization to chemotherapy. This guide adds a target-identity framework that connects BLM-focused assays with WRN-dependent MSI cancer research without conflating distinct RecQ helicases.

• Aging Impairs Macrophage Phagocytosis via Mitochondrial ROS

  2026-09-28

  This Aging Cell study identifies a mechanistic link between aging, mitochondrial reactive oxygen species, collagen overproduction, and defective macrophage phagocytosis. Its combination of human and mouse macrophage assays, transcriptomics, molecular perturbation, and in vivo validation suggests that restoring redox balance may improve antimicrobial macrophage function.

• Lamotrigine in BBB Transport and Channel Research

  2026-09-28

  Use Lamotrigine to connect sodium-channel pharmacology with carefully controlled BBB transport and efflux experiments—without assuming its permeability or transporter status in advance. A validated LLC-PK1-MDR1 workflow offers practical benchmarks for assay integrity, recovery, and follow-up studies.

• CFTRinh-172 for Reliable Epithelial Assays

  2026-09-27

  Learn how CFTRinh-172 (SKU B1435) can distinguish CFTR channel function from cell viability and trafficking effects in epithelial experiments. This practical guide covers controls, handling, data interpretation, and evidence-based product selection without treating functional inhibition as a cytotoxicity result.

8041 records 1/537 page Next 12345 下5页 Last page